Tumor heterogeneity confounds and illuminates: assessing the implications.
Certain biological features are inherent traits of cancer, yet some of them still hold mysteries for researchers and clinicians. The heterogeneity of a tumor mass is an old concept that has lately become both a puzzling factor and a feature that should be harnessed to better understand tumor vulnerabilities. Improved scientific approaches to further determine and uncover the meaning of these heterogeneous features are still needed to translate findings into ways to develop therapies, identify drug response biomarkers and stratify patients. In Bedside to Bench, Maria Kleppe and Ross L. Levine look at recent clinical cancer trials that have advanced the field and discuss main questions regarding the role of tumor heterogeneity in predicting therapeutic response and tumor progression. In addition, they raise awareness of the relevance of the interactions among different tumor entities and their contribution to the malignancy of the whole tumor. In Bench to Bedside, Kornelia Polyak peruses studies that uncover specific mutations conferring endocrine drug resistance in breast tumors and that add to our knowledge of the evolution and architecture of tumors, and she discusses how this can be used to implement drug regimens.
Human Oncology and Pathogenesis Program and Ross L. Levine is also a member of the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center. New York, New York, USA.
Maria
M
Kleppe
Human Oncology and Pathogenesis Program and Ross L. Levine is also a member of the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center. New York, New York, USA.
Ross L
RL
Levine
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D018450:Disease Progression; D059472:Exome; D018740:Genetic Heterogeneity; D005819:Genetic Markers; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics; D009101:Multiple Myeloma / Q000235:genetics; D009362:Neoplasm Metastasis / Q000235:genetics; D009369:Neoplasms / Q000235:genetics*; D017422:Sequence Analysis, DNA; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005819:Genetic Markers